RESUMEN
Bevacizumab, a monoclonal antibody against vascular endothelial growth factor, may be associated with arterial embolisms. We herein report a case of acute myocardial infarction caused by coronary embolism during combination chemotherapy with mFOLFOX-6 and bevacizumab in a patient with metastatic colon cancer. Thromboembolism occurred only in the distal right posterolateral branch without stenotic lesions or plaque rupture in the proximal branch of the right coronary artery. Sole thromboaspiration was successfully performed; the final angiogram demonstrated no stenosis in the right coronary artery. Bevacizumab may be associated with acute coronary syndrome in patients with coronary risk factors, despite no significant coronary narrowing.
Asunto(s)
Neoplasias del Colon , Enfermedad de la Arteria Coronaria , Embolia , Infarto del Miocardio , Neoplasias del Recto , Humanos , Bevacizumab/efectos adversos , Factor A de Crecimiento Endotelial Vascular , Neoplasias del Colon/tratamiento farmacológico , Enfermedad de la Arteria Coronaria/tratamiento farmacológico , Infarto del Miocardio/inducido químicamente , Infarto del Miocardio/tratamiento farmacológico , Neoplasias del Recto/tratamiento farmacológico , Embolia/inducido químicamenteRESUMEN
Bioprosthetic aortic valves have limited durability. We herein report sudden progression of structural valve deterioration (SVD) and a successful case of emergency transcatheter aortic valve (TAV) implantation for acute decompensated heart failure (ADHF) caused by SVD. A 79-year-old man who had undergone a Bentall operation 11 years prior was diagnosed with ADHF due to suddenly progressive SVD. Emergency TAV implantation in the surgical bioprosthetic valve was selected based on the surgical risk. Ours and previous case reports suggest that SVD can progress suddenly, even after months of stability, and that emergency TAV implantation is effective.
